BioSpace News Archive

Magnolia Medical Technologies, Inc. recently launched a new multi-media advertising campaign to promote the benefits of the Steripath® Initial Specimen Diversion Device® platform.

Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, today announced the launch of its new Agilon® Strip bone grafting product.

The report outlines actions to streamline study activation and maximize operational efficiency, making clinical research safer, smarter, and faster.

Heartland Dental has announced the hiring of Stacy DeWalt as the organization’s Executive Vice President, Chief Marketing Officer. DeWalt joins the company’s senior leadership team under the direction of Patrick Bauer, President and CEO.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021.

Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual Meeting.

Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that it will host a key opinion leader (KOL) webinar on LUM-201 on Tuesday, April 27, 2021, at 10:30am ET. LUM-201 is the Company’s orally administered therapeutic candidate for the treatment of pediatric growth hormone deficiency (PGHD).

Harrow Health, Inc., an ophthalmic-focused healthcare company, announced it has commenced an underwritten registered public offering of $25 million aggregate principal amount of senior notes due 2026, subject to market and certain other conditions.

Universal Health Services, Inc. (NYSE: UHS) announced today that it will report results for its first quarter ended March 31, 2021 after the market closes on Monday, April 26, 2021.

Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2020. Our net loss for the year ended December 31, 2020 was $6.4 million, or $0.07 per share, versus a net loss of $4.2 million, or $0.04 per share for the year ended December 31, 2019.